Last reviewed · How we verify
influenza trivalent inactive vaccine
Inova Health Care Services markets an influenza trivalent inactive vaccine, positioning it in a competitive but essential seasonal vaccination market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports current market presence. The primary risk lies in the potential increase in competition post-patent expiry, which could impact revenue and market share.
At a glance
| Generic name | influenza trivalent inactive vaccine |
|---|---|
| Also known as | Fluzone(R), flu vaccine |
| Sponsor | Inova Health Care Services |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant. (PHASE4)
- Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients (PHASE3)
- Immune Response of Intradermal and Intramuscular Preparations of Inactive Seasonal Influenza Vaccine in Older Age Group. (PHASE4)
- A Randomized, Controlled Trial on the Efficacy and Safety of Live-Attenuated Influenza Vaccine (LAIV) Among Children in Bangladesh (PHASE3)
- Clinical Efficacy of Trivalent Live-Attenuated Influenza Vaccine (LAIV) Among Children in Senegal (PHASE3)
- Safety and Immunogenicity of a Single Dose of Intranasal Seasonal Trivalent Live-Attenuated Influenza Vaccine (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |